373 related articles for article (PubMed ID: 27118999)
41. Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas.
Oster B; Thorsen K; Lamy P; Wojdacz TK; Hansen LL; Birkenkamp-Demtröder K; Sørensen KD; Laurberg S; Orntoft TF; Andersen CL
Int J Cancer; 2011 Dec; 129(12):2855-66. PubMed ID: 21400501
[TBL] [Abstract][Full Text] [Related]
42. 5' CpG island methylation analysis identifies the MAGE-A1 and MAGE-A3 genes as potential markers of HCC.
Qiu G; Fang J; He Y
Clin Biochem; 2006 Mar; 39(3):259-66. PubMed ID: 16516880
[TBL] [Abstract][Full Text] [Related]
43. Association of interindividual differences in p14ARF promoter methylation with single nucleotide polymorphism in primary colorectal cancer.
Kang MY; Lee BB; Ji YI; Jung EH; Chun HK; Song SY; Park SE; Park J; Kim DH
Cancer; 2008 Apr; 112(8):1699-707. PubMed ID: 18327804
[TBL] [Abstract][Full Text] [Related]
44. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
45. Methylation-specific PCR.
Licchesi JD; Herman JG
Methods Mol Biol; 2009; 507():305-23. PubMed ID: 18987823
[TBL] [Abstract][Full Text] [Related]
46. Methylation-Specific PCR.
Ramalho-Carvalho J; Henrique R; Jerónimo C
Methods Mol Biol; 2018; 1708():447-472. PubMed ID: 29224158
[TBL] [Abstract][Full Text] [Related]
47. A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients.
Nakayama G; Hibi K; Nakayama H; Kodera Y; Ito K; Akiyama S; Nakao A
Anticancer Res; 2007; 27(3B):1459-63. PubMed ID: 17595762
[TBL] [Abstract][Full Text] [Related]
48. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.
Mikeska T; Bock C; El-Maarri O; Hübner A; Ehrentraut D; Schramm J; Felsberg J; Kahl P; Büttner R; Pietsch T; Waha A
J Mol Diagn; 2007 Jul; 9(3):368-81. PubMed ID: 17591937
[TBL] [Abstract][Full Text] [Related]
49. MGMT promoter methylation and field defect in sporadic colorectal cancer.
Shen L; Kondo Y; Rosner GL; Xiao L; Hernandez NS; Vilaythong J; Houlihan PS; Krouse RS; Prasad AR; Einspahr JG; Buckmeier J; Alberts DS; Hamilton SR; Issa JP
J Natl Cancer Inst; 2005 Sep; 97(18):1330-8. PubMed ID: 16174854
[TBL] [Abstract][Full Text] [Related]
50. Altered regulation of DNA ligase IV activity by aberrant promoter DNA methylation and gene amplification in colorectal cancer.
Kuhmann C; Li C; Kloor M; Salou M; Weigel C; Schmidt CR; Ng LW; Tsui WW; Leung SY; Yuen ST; Becker N; Weichenhan D; Plass C; Schmezer P; Chan TL; Popanda O
Hum Mol Genet; 2014 Apr; 23(8):2043-54. PubMed ID: 24282031
[TBL] [Abstract][Full Text] [Related]
51. A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing.
Mack E; Stabla K; Riera-Knorrenschild J; Moll R; Neubauer A; Brendel C
BMC Cancer; 2016 Aug; 16():585. PubMed ID: 27485514
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
Ogino S; Kawasaki T; Kirkner GJ; Kraft P; Loda M; Fuchs CS
J Mol Diagn; 2007 Jul; 9(3):305-14. PubMed ID: 17591929
[TBL] [Abstract][Full Text] [Related]
53. Quantitative DNA Methylation Analysis at Single-Nucleotide Resolution by Pyrosequencing®.
Busato F; Dejeux E; El Abdalaoui H; Gut IG; Tost J
Methods Mol Biol; 2018; 1708():427-445. PubMed ID: 29224157
[TBL] [Abstract][Full Text] [Related]
54. A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR.
Claus R; Wilop S; Hielscher T; Sonnet M; Dahl E; Galm O; Jost E; Plass C
Epigenetics; 2012 Jul; 7(7):772-80. PubMed ID: 22647397
[TBL] [Abstract][Full Text] [Related]
55. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
[TBL] [Abstract][Full Text] [Related]
56. Hypermethylation of CpG island in the promoter region of CALCA in acute lymphoblastic leukemia with central nervous system (CNS) infiltration correlates with poorer prognosis.
Paixão VA; Vidal DO; Caballero OL; Vettore AL; Tone LG; Ribeiro KB; Lopes LF
Leuk Res; 2006 Jul; 30(7):891-4. PubMed ID: 16712930
[TBL] [Abstract][Full Text] [Related]
57. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
Xie H; Tubbs R; Yang B
Int J Clin Exp Pathol; 2015; 8(2):1790-6. PubMed ID: 25973069
[TBL] [Abstract][Full Text] [Related]
58. Comparison of bisulfite sequencing PCR with pyrosequencing for measuring differences in DNA methylation.
Reed K; Poulin ML; Yan L; Parissenti AM
Anal Biochem; 2010 Feb; 397(1):96-106. PubMed ID: 19835834
[TBL] [Abstract][Full Text] [Related]
59. Primer design versus PCR bias in methylation independent PCR amplifications.
Wojdacz TK; Borgbo T; Hansen LL
Epigenetics; 2009 May; 4(4):231-4. PubMed ID: 19483476
[TBL] [Abstract][Full Text] [Related]
60. Analysis of promoter CpG island hypermethylation in cancer: location, location, location!
van Vlodrop IJ; Niessen HE; Derks S; Baldewijns MM; van Criekinge W; Herman JG; van Engeland M
Clin Cancer Res; 2011 Jul; 17(13):4225-31. PubMed ID: 21558408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
